Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Bifidobacterium breve M-16V is a clinically studied probiotic strain that produces short-chain fatty acids and bacteriocins to support gut health. This strain modulates immune responses through Toll-like receptor pathways and enhances intestinal barrier function in infants and adults.
Reported Benefits (Provisional)
Origin & History
Bifidobacterium breve M-16V is a probiotic strain isolated from human breast milk. It is cultivated in controlled environments to ensure purity and efficacy. This strain is particularly noted for its role in infant gut health.
Research Narrative (Provisional)
Clinical trials have shown its efficacy in improving gut health and reducing allergic symptoms in infants. Meta-analyses support its role in immune system development.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Produces short-chain fatty acids beneficial for gut health. - High in bifidogenic activity, promoting beneficial bacteria growth. - Contains enzymes that aid in lactose digestion.
Reported Mechanism (Provisional)
Bifidobacterium breve M-16V produces acetate and lactate through carbohydrate fermentation, creating an acidic environment that inhibits pathogenic bacteria. The strain activates regulatory T-cells via dendritic cell interaction and TLR2/TLR4 pathways, promoting anti-inflammatory cytokine IL-10 production. It strengthens intestinal barrier function by upregulating tight junction proteins claudin-1 and occludin.
Clinical Narrative (Provisional)
Multiple randomized controlled trials involving over 800 infants have demonstrated M-16V's efficacy in preventing necrotizing enterocolitis and reducing infection rates by 40-60%. A 12-week study with 90 allergic infants showed 35% reduction in eczema severity scores compared to placebo. Respiratory health studies in 200+ children demonstrated 25% fewer upper respiratory infections and reduced inflammatory markers including decreased IL-6 levels. Evidence quality is moderate to high for infant applications, with emerging data for adult benefits.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.